Sandra Bohorquez‐Blanco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sandra Bohorquez‐Blanco has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Constanza Couve‐Pérez
Department of Gynecology and Obstetrics Division of Maternal and Fetal Medicine Faculty of Medicine Universidad de Valparaíso Hospital Dr. Gustavo Fricke Viña del Mar Chile
1 shared publication - Cynthia Carrasco
Interdisciplinary Center for Health Studies (CIESAL Universidad de Valparaíso Cochrane Chile Associate Center Valparaíso Chile
1 shared publication - Eva Madrid
Cochrane Evidence Synthesis Unit Iberoamérica, Interdisciplinary Centre for Health Studies (CIESAL); Universidad de Valparaíso; Viña del Mar Chile
1 shared publication - Javier Bracchiglione
Institut de Recerca Sant Pau (IR SANT PAU) Sant Quintí Barcelona Spain
1 shared publication - Laura Vergara-Merino
Departamento Ortopedia y Traumatología, Pontificia Universidad Católica, Santiago, Chile
1 shared publication - Luis E. Ortiz-Muñoz
UC Evidence Center, Cochrane Chile Associated Center, Pontificia Universidad Catolica de Chile, Santiago, Chile
1 shared publication
Latest Publications
- Open Access
- 9 February 2021
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 100 (7) , 1200-1218
Maternal and perinatal outcomes related to COVID‐19 and pregnancy: An overview of systematic reviews
Introduction: Evidence about coronavirus disease 2019 (COVID‐19) and pregnancy has rapidly increased since December 2019, making it difficult to make rigorous evidence‐based decisions. The objective of this overview of systematic reviews is to conduct a comprehensive analysis of the current evidence on prognosis of COVID‐19 in pregnant women.Material and methods: We used the Living OVerview of Evidence (L·OVE) platform for COVID‐19, which continually retrieves studies from 46 data sources (including PubMed/MEDLINE, Embase, other electronic databases, clinical trials registries, and preprint repositories, among other sources relevant to COVID‐19), mapping them into PICO (population, intervention, control, and outcomes) questions. The search covered the period from the inception date of each database to 13 September 2020. We included systematic reviews assessing outcomes of pregnant women with COVID‐19 and/or their newborns. Two authors independently screened the titles and abstracts, assessed full texts to select the studies that met the inclusion criteria, extracted data, and appraised the risk of bias of each included systematic review. We measured the overlap of primary studies included among the selected systematic reviews by building a matrix of evidence, calculating the corrected covered area, and assessing the level of overlap for every pair of systematic reviews.Results: Our search yielded 1132 references. 52 systematic reviews met inclusion criteria and were included in this overview. Only one review had a low risk of bias, three had an unclear risk of bias, and 48 had a high risk of bias. Most of the included reviews were highly overlapped among each other. In the included reviews, rates of maternal death varied from 0% to 11.1%, admission to intensive care from 2.1% to 28.5%, preterm deliveries before 37 weeks from 14.3% to 61.2%, and cesarean delivery from 48.3% to 100%. Regarding neonatal outcomes, neonatal death varied from 0% to 11.7% and the estimated infection status of the newborn varied between 0% and 11.5%.Conclusions: Only one of 52 systematic reviews had a low risk of bias. Results were heterogeneous and the overlap of primary studies was frequently very high between pairs of systematic reviews. High‐quality evidence syntheses of comparative studies are needed to guide future clinical decisions.
- 9 February 2021
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 100 (7) , 1200-1218
Open AccessMaternal and perinatal outcomes related to COVID‐19 and pregnancy: An overview of systematic reviews
Introduction: Evidence about coronavirus disease 2019 (COVID‐19) and pregnancy has rapidly increased since December 2019, making it difficult to make rigorous evidence‐based decisions. The objective of this overview of systematic reviews is to conduct a comprehensive analysis of the current evidence on prognosis of COVID‐19 in pregnant women.Material and methods: We used the Living OVerview of Evidence (L·OVE) platform for COVID‐19, which continually retrieves studies from 46 data sources (including PubMed/MEDLINE, Embase, other electronic databases, clinical trials registries, and preprint repositories, among other sources relevant to COVID‐19), mapping them into PICO (population, intervention, control, and outcomes) questions. The search covered the period from the inception date of each database to 13 September 2020. We included systematic reviews assessing outcomes of pregnant women with COVID‐19 and/or their newborns. Two authors independently screened the titles and abstracts, assessed full texts to select the studies that met the inclusion criteria, extracted data, and appraised the risk of bias of each included systematic review. We measured the overlap of primary studies included among the selected systematic reviews by building a matrix of evidence, calculating the corrected covered area, and assessing the level of overlap for every pair of systematic reviews.Results: Our search yielded 1132 references. 52 systematic reviews met inclusion criteria and were included in this overview. Only one review had a low risk of bias, three had an unclear risk of bias, and 48 had a high risk of bias. Most of the included reviews were highly overlapped among each other. In the included reviews, rates of maternal death varied from 0% to 11.1%, admission to intensive care from 2.1% to 28.5%, preterm deliveries before 37 weeks from 14.3% to 61.2%, and cesarean delivery from 48.3% to 100%. Regarding neonatal outcomes, neonatal death varied from 0% to 11.7% and the estimated infection status of the newborn varied between 0% and 11.5%.Conclusions: Only one of 52 systematic reviews had a low risk of bias. Results were heterogeneous and the overlap of primary studies was frequently very high between pairs of systematic reviews. High‐quality evidence syntheses of comparative studies are needed to guide future clinical decisions.